A Phase 2/3 interventional study of Apixaban and Enoxaparin in Venous Thrombosis and Pulmonary Embolism, sponsored by Bristol-Myers Squibb. Completed at 148 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2010-03-02.
Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.
Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 9th largest by enrollment, is the only one that started in 2004, is one of 2 in phase 2/3, and was the 1st registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Rushad Patell · Sites in United States
Ages 18+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
James Bayley · Sites in United States
Ages 18+
University Hospital, Geneva
Ages 18–120
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 12 · Phase 4 10
First in 2004; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,238 is above the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 445 across the 26 interventional studies. Of the 19 that completed or were terminated, 11 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 26 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Venous Thrombosis — fewer than ten, so there is no comparison to draw.
3 of the studies testing apixaban in Venous Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07713875James BayleyExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic Disease | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing apixaban in Venous Thrombosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apixaban: 2.5 mg, BID PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Apixaban: 5 mg, BID PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Apixaban: 10 mg, BID PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Apixaban: 5 mg, QD PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Apixaban: 10 mg, QD PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Apixaban: 20 mg, QD PLUS Enoxaparin Placebo
Drug: Apixaban · Drug: Enoxaparin Placebo
Enoxaparin: 30 mg PLUS Apixaban Placebo
Drug: Enoxaparin · Drug: Apixaban Placebo
Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
Drug: Warfarin
Tablets, Oral, 12 +/- 2 days
Also known as: BMS-562247
Injection, SQ, Q12H, 12 +/- 2 days
Tablets, Oral, QD, 12 +/- 2 days
Injection, SQ, BID, 12 +/- 2 days
Tablets, Oral, BID, 12 +/- 2 days
Determine the dose-response relationship among the 3 QD and 3 BID doses of BMS-562247 on the composite endpoint of adjudicated VTE events and all-cause death in subjects treated with study medication for 12 +/-2 days following surgery
Time frame: throughout the study
Assess the effect of QD and BID dose of BMS-562247 vs subcutaneous 30 mg q12h enoxaparin and warfarin on the composite endpoint of adjudication VTE events and all-cause death in subjects treated for 12 +/-2 days following surgery
Time frame: throughout the study
Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated major bleeding events in subjects treated with study medication for 12 +/-2 days following surgery
Time frame: throughout the study
Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated minor bleeding events in subjects treated with study medication for 12 +/-2 days following surgery
Time frame: throughout the study
To determine the pharmacokinetic (PK) profile of BMS-562247 and the relationship to dose and dose schedule
Time frame: throughout the study
Showing the first 100 of 148 sites across 9 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2004, a primary completion of Dec 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban